Incyte (INCY) Misses Q1 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Incyte (INCY) Misses Q1 EPS by 14c

Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 3, 2022 7:00 AM EDT

Total product and royalty revenues of $728 million in Q122 (+20% Y/Y) Jakafi® (ruxolitinib) net product revenues of $544 million in Q122 (+17% Y/Y); raising the bottom end of full year guidance to new range of $2.33 to $2.40 billion Robust uptake of Opzelura (ruxolitinib) cream with over 38,000 new patients treated in the first quarter; meaningful progress with payers resulting in 146 million total lives now covered Positive 52-week data from the Phase 3 TRuE-V program evaluating ruxolitinib cream in patients with vitiligo presented at AAD 2022; ruxolitinib cream is currently under review in the U.S. and... More